12 Health Care Stocks Moving In Thursday's After-Market Session
GainersTwist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out to
Express News | Orchestra Biomed Announces Avim Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
Express News | Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Piper Sandler Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)
Express News | Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data
Orchestra BioMed Holdings 2023 Loss/Shr $1.48 >OBIO
Orchestra BioMed Holdings 2023 Loss/Shr $1.48 >OBIO
Orchestra BioMed Holdings 2023 Rev $2.8M >OBIO
Orchestra BioMed Holdings 2023 Rev $2.8M >OBIO
Press Release: Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update -- Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (al
Press Release: Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors -- David Pacitti is currently the President of Siemens Medical Solutions USA, Inc
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline With Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
New pharmacokinetic data demonstrate Virtue SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within
Orchestra BioMed Unveils Investor Presentation Update
Orchestra BioMed Announces Presentation of Results From Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate statistically significant
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated With AVIM Therapy for Over 3 Years
8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study Orchestra BioMed is actively enrolling
Jefferies Starts Orchestra BioMed at Buy, Cites Lead Program Opportunities
Express News | Jefferies Initiates Coverage On Orchestra BioMed Hldgs With Buy Rating, Announces Price Target of $14
Orchestra BioMed Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/19/2024 85.92% Jefferies → $14 Initiates Coverage On → Buy 08/11/2023 165.6% Chardan Capital → $20 Reit
Orchestra BioMed Begins Pivotal Trial of Cardiac Neuromod Tech
Express News | Orchestra BioMed Says First Patient Was Randomized In The BACKBEAT Pivotal Study In Late December 2023
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be mo
No Data